EXEN
Exenatide
A synthetic 39-amino-acid peptide with the sequence of exendin-4, identified in the venom of the Gila monster, Heloderma suspectum. It shares roughly half its sequence with human GLP-1 and binds the same receptor. Its glycine at position 2 is what makes it resistant to dipeptidyl peptidase-4, the enzyme that cleaves native GLP-1 within minutes.
Exenatide has 279 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 53,764 planned or enrolled participants across the 262 studies that published a figure. An FDA-approved product contains Exenatide — BYETTA (NDA021919). 1,434 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Exenatide; the registry search is fuzzy, so every match is re-checked. None of this says whether Exenatide works or is safe.
FDA status
Approved
Human studies
279
Furthest phase
Phase 4
Papers, 10 yr
1,434
Readership
3,088
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
279
Registered human studies
Phase 4
Furthest phase reached
53,764
Planned or enrolled participants, across 262 studies that published a figure
Approved
FDA-approved product — BYETTA
377 loose registry matches were checked and 279 confirmed — 98 named something else and were discarded. We count a study only when Exenatide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Exenatide is, and what it has been studied for
Exenatide is classified by ChEMBL as a protein, and appears in trial registrations under AC-002993 and AC002993. Its FDA substance identifier is 9P1872D4OL.
Across 279 registered trials, it has been studied in Type 2 Diabetes Mellitus, Type 2 Diabetes and Obesity. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by AstraZeneca and Amsterdam UMC, location VUmc among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Exenatide reached Phase 4 across 279 registered trials.
An FDA-approved product contains Exenatide. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Exenatide?
Papers published each year that name Exenatide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 187 | 15 | Yes |
| 2018 | 168 | 5 | Yes |
| 2019 | 179 | 5 | Yes |
| 2020 | 153 | 5 | Yes |
| 2021 | 158 | 7 | Yes |
| 2022 | 119 | 2 | Yes |
| 2023 | 130 | 2 | Yes |
| 2024 | 143 | 4 | Yes |
| 2025 | 195 | 0 | Yes |
| 2026 | 164 | 1 | No |
1,434 papers and 46 registered trials between 2017 and 2026. A paper counts when “Exenatide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Exenatide
1,434 indexed papers name Exenatide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
- Exenatide
- Exenatide
- Exenatide
- Exenatide
- Exenatide
- Exenatide. Amylin/Eli Lilly
- Exenatide
Collected 2026-08-02from PubMed, phrase-matched on “Exenatide” in title and abstract. Run the same search.
About Exenatide
A synthetic 39-amino-acid peptide with the sequence of exendin-4, identified in the venom of the Gila monster, Heloderma suspectum. It shares roughly half its sequence with human GLP-1 and binds the same receptor. Its glycine at position 2 is what makes it resistant to dipeptidyl peptidase-4, the enzyme that cleaves native GLP-1 within minutes.
- Also known as
- AC2993
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.